Alternatively, and in accordance with previous studies, TET2, DNMT3A, and TET3 were sometimes observed in the myeloid or B‐cell fraction in addition to the tumor indicating it was likely an early founding mutation that occurred in a progenitor cells [38, 39]. The gene discussed is TET3; the disease is neoplasm.